Introducing Nanovent

Nanovent is a Cambridge based start-up created to enable technology transfer, and develop a range of innovative products and services. We are experts in polymeric materials for health care applications such as  Medical coating, contact lens, smart wound care solution, nano-carriers-drug delivery and more.  We deliver technical and solution-based projects across materials design, feasibility studies, process development, scaling up and technology transfer for short and long term contracts.
We are agile, skillful and work at speed to provide cost-cutting solution.

5f735827b86694388a2a202e_Inventya Logo.p
download.png

Over 13 million people worldwide suffer from acute or chronic wounds every year. These wounds are managed both in hospitals and in community care. The patients suffering from these wounds report physical, mental and social consequences of their wounds and the care of them. The annual cost for acute or chronic wound treatment exceeds 15 billion dollars. Nanovent's Smart NanoSTAR technology can be successfully applied to improve the efficacy of wound management, and our innovation is embedded in polymer composition, manufacturing and infrastructure to investigate new formulations in clinically-relevant smart wound care models. Smart nanoSTAR formulated technology, with improved efficiency could replace existing wound care management, resulting in better quality of life for patients with disease.

WE ARE LOOKING FOR POTENTIAL INVESTMENT TO BRING THIS TECHNOLOGY INTO PRACTICE.

Prostate cancer (PCa) is the most diagnosed male cancer, with +1.2M new cases annually and +350,000 deaths worldwide (WorldJOncol.2019,10:63-89). Global CRPC therapeutics market is valued at $9.3Bn in 2020 and is expected to reach $16.2Bn by 2027, expanding at a 8.4% CAGR 2020-2027 (GrandViewResearch,GVR-4-68039-237-3,2020). Nanovent and its academic collaborators are proposing a novel nanocarrier platform technology based on STAR architecture polymer composition (NanoSTAR). Innovation is embedded in polymer composition, method of manufacturing and infrastructure to investigate new formulations in clinically-relevant prostate cancer models. Our innovative NanoSTAR technology has the potential to improve drug accumulation at sites of action, thereby improving the clinical efficacy of cancer drugs.

WE ARE LOOKING FOR POTENTIAL INVESTMENT TO BRING THIS TECHNOLOGY INTO PRACTICE.